The XANIX+ division, last but not least, deals with the development and commercialization of molecules intended for human health.

It owes its development to the synergy that has been created over time with the logistics division, in fact it is thanks to the versatility of the latter that we have gone from the management of the finished product handled, to direct participation with the production laboratories of the same product.

It was precisely by concentrating research and resources on disinfection and sanitization, mainly in the human and animal fields, that a stable, high-performance molecule with an efficacy of 99.9% was created

In addition, the ease of production, the speed of distribution globally, and the different formats/supports have decreed its success, especially in disadvantaged areas, which are particularly difficult to reach and therefore distribute.